Delayed‐type reactivity to catcipotriol without cross‐sensitization to tacalcitol

Zollner, Thomas M.; Ochsendorf, Falk; Hensel, O.; Thaçi, Diamant; Diehl, Sandra; Kalveram, C. M.; Boehncke, Wolf‐Henning; Wolter, M.; Kaufmann, Roland

doi:10.1111/j.1600-0536.1997.tb02457.x

Cited by 9 publications

(15 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Interestingly, Zollner et al. were able to confirm their positive patch test result with a positive lymphocyte proliferation test result . According to the latter, patients sensitized to calcipotriol may tolerate topical therapy with tacalcitol, which was later confirmed by other authors .…”

Section: Discussionmentioning

confidence: 82%

Allergic contact dermatitis caused by calcipotriol

2017

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 82%

Allergic contact dermatitis caused by calcipotriol

2017

View full text Add to dashboard Cite

show abstract

“…The cases reported by Zollner et al ( 12 ) and Frosch & The toxicity of calcipotriol is low but human trials Rustemeyer (10 ) are clearly contact allergy to calcipohave shown that it may elevate the serum calcium triol. This report adds a typical case of allergic contact levels ( 8).…”

Section: Discussionmentioning

confidence: 92%

Allergic Contact Dermatitis from Calcipotriol

Park¹,

Lee²,

Chung³

2002

Acta Dermato-Venereologica

View full text Add to dashboard Cite

“…1 [18.75-37.55], p = 0.026. IGA improved from a median of 4 [3][4] Clinical improvement in eczema severity during the treatment period was accompanied by a significant reduction in the requirement for potent topical corticosteroids (p = 0.033) and number of hospital-contacts for eczema (p = 0.082). Conclusions: TLA treatment leads to a significant clinical improvement in children with severe atopic eczema, with accompanying reduction in medication usage and healthcare utilization.…”

Section: Methodsmentioning

confidence: 93%

“…In order to avoid irritant patch test reactions, a concentration of 2 µg/ml in isopropyl alcohol is the most suitable, and in unclear cases, a repeated open application test (ROAT) should be performed [3]. According to the literature, patients sensitized to calcipotriol may tolerate topical therapy with other vitamin D analogues, in particular tacalcitol [4].…”

Section: Discussionmentioning

confidence: 99%

EAACI/ESCD Skin Allergy Meeting 2017 (SAM 2017)

2017

Clin Transl Allergy

View full text Add to dashboard Cite

Background: Methylisothiazolinone (MI) is used as a preservative in occupational, domestic products and, since 2005, in cosmetics. It is a part of the preparation of methylchloroisothiazolinone (MCI)/MI and only in the last years started to be tested as a single allergen in the baseline series. According to recent studies, the sensitization rate for MI varies between 1 and 6%, with a marked increase, particularly in the late years. Objectives: To describe patients sensitized to MI and MCI/MI and investigate its prevalence among patch tested patients Methods: Cross-sectional retrospective study, including all patients who performed, from 2011 to 2016, the European and Portuguese baseline patch test series, in a Dermatology department of a tertiary hospital. Those positive to MI and/or MCI/MI, were selected. Results: During the study period, 1768 patients (70% women), performed the baseline series; 972 (55%) tested positive according to the International Contact Dermatitis Research Group's scoring system. Of these, 114 individuals (11.7%) presented positivity to MI and/or MCI/ MI; 81 (71%) were women; mean age (minimum-maximum) of 44.3 (8-86) years; 33.3% had previous history of atopic comorbidities. Hands either isolated or associated with other body parts were the most frequent symptomatic location (54 cases, 47.4%) followed by generalized dermatitis (33 cases, 29%). Further comparison of MI sensitization revealed no significant differences with respect to gender (p = 0.267), age (p = 0.616), or the presence of allergic comorbidities (p = 0.536). In 2011, only one patient (0.3%) tested positive to MCI/MI and after June 2012 patients (1.1%) were positive to MI. After 2012 we observed a significant increase in

show abstract

Delayed‐type reactivity to catcipotriol without cross‐sensitization to tacalcitol

Cited by 9 publications

References 7 publications

Allergic contact dermatitis caused by calcipotriol

Allergic contact dermatitis caused by calcipotriol

Allergic Contact Dermatitis from Calcipotriol

EAACI/ESCD Skin Allergy Meeting 2017 (SAM 2017)

Contact Info

Product

Resources

About